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Abstract: Aberrant transcriptional activities have been documented in breast cancers. Studies often find some transcription factors to be 
inappropriately regulated and enriched in certain pathological states. The promoter regions of most target genes have binding sites for 
their transcription factors. An ample of evidence supports their combinatorial effect on their shared target gene expressions.
Here, we used a new statistic method, bivariate CID, to predict combinatorial interaction activity between ERα and a transcription factor 
(E2F1or GATA3 or ERRα) in regulating target gene expression via four regulatory mechanisms. We identified gene sets in three signal 
transduction pathways perturbed in breast tumors: cell cycle, VEGF, and PDGFRB. Bivariate network analysis revealed several target 
genes previously implicated in tumor angiogenesis are among the predicted shared targets, including VEGFA, PDGFRB. In summary, 
our analysis suggests the importance for the multivariate space of an inferred ERα transcriptional regulatory network in breast cancer 
diagnostic and therapeutic development.
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Introduction
To  better  characterize  estrogen  receptor  positive 
(ER(+)) breast cancer has its importance when tradi-
tional pathological information can not fully evaluate 
the clinical outcomes of patients, especially for those 
who eventually have worse prognosis. Oh et al1 iden-
tified two subtypes of ER(+) breast cancers, group IE 
and group IIE, to be clinically distinct in their estrogen 
induced functional estrogen receptor α (ERα) activi-
ties in addition to their intrinsic phenotypes at molec-
ular level (e.g. Normal like, luminal A and B). Our 
research findings2 also suggested that aberrant ERα 
phenotype in breast cancer may be demonstrated by 
ERα directed transcriptional regulatory network, at 
least in part. We thus hypothesize that the ongoing pro-
moter use pathways within the functional ERα tran-
scriptional regulatory network may provide insights 
into a better understanding the transcriptional regula-
tory activities of both ERα alone and ERα with other 
transcription factor(s) (TFs) on ERα target genes in 
breast cancer.
Both  regular  and  alternative  promoter  uses  of 
ERα to its target genes have been studied intensively 
in vitro.3–7 Davuluri et al7 pointed out the proposed 
mechanisms of promoter use that may be different 
between tumor and normal cells. The above research 
evidence, in part, supported our hypothesis that some 
of the clinical pathophenotypic differences between 
groups IE and IIE breast cancers may be derived 
from the alternative promoter use pathways of ERα 
and/or other TFs on their shared target genes. In 
theory, the clue of subtype specific promoter use on 
subsets of genes in the ERα transcriptional regula-
tory network would assist in functional subtyping of 
ER(+) breast cancers.
In this study, we aimed at building up a network 
with  clusters  of  gene  sets  based  on  their  relevant 
nature of promoter use, and filling the multivariate 
space  of  the  previously  established  network.2 This 
effort is proposed to be achieved by applying univari-
ate and multivariate versions of coefficient of intrin-
sic dependence (CID) as well as the Galton Pearson’s 
correlation coefficient (GPCC) to statistically iden-
tify the promoter use mechanisms for shared target 
genes of functional transcription factors in a given 
  population.  CID  in  combination  with  GPCC  for 
measuring    univariate  association  has  been  applied 
to  identify  both  direct  and  remote  associations  of 
  TF-target (Liu et al. 2009).2 Here, we would propose 
that CID itself should be able to evaluate the associa-
tion between two transcription factors (e.g. ERα and 
other TF) and one of their shared target genes when 
ERα may interact with a TF, which is one of ERα 
primary target genes. The simultaneous or sequen-
tial interaction between ERα and other TF results in 
regulating the expression of their shared target gene 
that is predicted to occur. Such regulatory associa-
tion is expected to be recognized by one version of 
multivariate CID called bivariate CID (see Methods). 
Three  pairs  of  transcription  factors  (ERα,  E2F1), 
(ERα, GATA3) and (ERα, ERRα) were used to test 
this  hypothesis.  Finally,  we  briefly  predicted  how 
interactions of ERα with three transcription partners 
to achieve a visible pathological phenotype, which is 
a new clinical parameter, based on results of bivari-
ate CID. The transcriptional regulatory mechanisms 
of those interactions may interpret a transcriptional 
switch made for altering pre-programmed physiolog-
ical state to a pathophysiological state.
Methods
Clinical breast cancer expression arrays
The  one  hundred  and  ninety  nine  clinical  arrays 
(abbreviated as “199A”) were from a patient cohort 
(started from 1998 to 2007) collected at National 
  Taiwan  University  Hospital  (NTUH).  The  tumor 
samples, defined by average greater than 50% tumor 
cells  per  high-power  field  examined  in  a  section 
adjacent to the   tissue used,8 were included in this 
study. These clinical arrays were generated using 
the Human 1A (version 2) oligonucleotide microar-
ray (Agilent   technologies, USA) according to the 
  methods  provided  by  the  manufacture.  The  pre-
  processing, normalization of microarray data were 
performed following methods described.8 The total 
array content is half a genome not a whole genome. 
This  will  influence  the  size  of  gene  pools  to  be 
extracted in silico for building a network described 
in this study. All patients had given informed consent 
according to guidelines approved by the Institutional 
Review  Board  (IRB)  at  NTUH.  The  dataset  can 
be  retrieved  at  NCBI-GEO  (accession  number 
GSE24124). Three subsets of the clinical arrays were 
used in the analyses. The first data set (abbreviated 
as “152A”) included group IE breast cancer (61A) 
and ER(-) breast cancer (91A). Both ERα  status Actions of transcription factors on shared target genes
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and   progesterone receptor A (PR) status are   positive 
for  group  IE  breast  cancer.1  The  second  data  set 
(abbreviated as “120A”) included group IIE breast 
cancer (29A) and ER(-) breast   cancer (91A). Group 
IIE has positive ERα status and negative PR status1 
(Table S10). As a control of this study, we selected 
the third data set including   eighteen non-tumor sam-
ples (18A) that were surgically taken from breast tis-
sue adjacent to some of 90 IDC breast tumors with 
ER(+) described below.
Immunohistochemical staining of eRα 
and progesterone receptor A (PR)
All  the  paraffin  sections  of  breast  cancer  speci-
mens  (3–5  µm  in  thickness)  on  slides  were  pro-
cessed  in    Ventana’s  automated  staining  system 
(BenchMark®  LT)  (Ventana  Medical  Systems,  Inc) 
for  the  immunohistochemical  stain  (IHC). All  the 
procedure for IHC stain has been documented.2 To 
detect the IHC of progesterone receptor A, mouse 
anti-human PGR monoclonal antibody, unconjugated 
clone  5D10  (Catalog  #  H00005241-M07,  Abnova 
Corporation, Taiwan) with dilution ratio at 1:50 was 
used as the specific antibody to bind PR protein on 
the tumor section of 181 samples. And, the definition 
of positive IHC stain for ERα protein (ER(+)) or PR 
protein (PR(+)) in this study is for tumor slide that has 
shown greater than or equal to 10% tumor cells with 
moderate to high amount of immunoreactive nuclear 
ERα  protein  or  PR  protein.  To  prevent  extracting 
less meaningful data in this study, we used both IHC 
and real-time quantitative polymerase chain reaction 
(QPCR) data of both ERα and PR (data not shown) to 
be the supporting information for this study.
Statistical analysis on univariate 
association between a TF and  
a target gene using part of gene 
expression dataset from 181A
The  statistical  methods  applied  for  identifying 
the  gene  lists  of  estrogen  regulated  transcriptional 
activities were the univariate association measured 
by  the  coefficient  of  intrinsic  dependence  (CID)2,9 
and that by Galton-Pearson’s correlation coefficient 
(GPCC).2  The  univariate  CID  result  for  a  given 
TF was   designated as CID-TF. Instead of all sub-
groups   having an equal size (N ≈ 10),2 we divided 
the  cohort  by  hierarchical  clustering  (described  in 
method below) to mimic   biological systems in which 
similar expression pattern in a subgroup may reflect 
the similar biological event shared by the members 
within a subgroup. As a result, the subgroup was des-
ignated as j. For instance, each subCID value of the 
assigned subgroup (  j) is determined in part by the 
sample size of the subgroup j, a constant value and 
the two times square of difference between cumula-
tive   distribution function (CDF) of gene Y in the sub-
group j and the average CDF of gene Y in a given 
population. Total CID value demonstrates the degree 
of dependence between TF and its target gene.2 We 
have optimized number of subgroups chosen for CID 
measurements. That is, we set rounding number for 
one tenth of total array numbers as the final number of 
subgroups (15 subgroups for 152A) after expression 
profile of a variable was hierarchically pre-clustered 
in a given population. The GPCC measures the linear 
expression relationship between the TF and its target 
gene. The univariate association results were derived 
by  combining  CID-TF  and  GPCC  (designated  as 
CID-TFUGPCC).2
eRα_e2F1, eRα_gATA3 and  
eRα_eRRα pathways predicted  
in silico by bivariate CId
There are four steps included in this analysis. The anal-
ysis of ERα_E2F1 pathway is demonstrated here as an 
example (Fig. 2A). First, a scatter plot for mRNA levels 
of two TFs was produced. The left panel in   Figure 2A 
provided an example demonstrating the scatter plot of 
E2F1 mRNA versus ESR1 mRNA in 152A. A scatter 
plot represents a two-dimensional scattering pattern 
of two co-expressed TFs of interest at mRNA level. 
Second, a hierarchical clustering10 based on the dis-
tances  between  spots  and  between  groups  of  spots 
was performed. In this study, the   distance between 
two spots was described by   Euclidean Distance (i.e. 
D =  () () xx yy ij ij −+ −
22 , where (xi, yi) are mRNA 
levels of (TF1, TF2) for the ith spot). The distance 
between two groups of spots was defined by complete 
linkage, which is the Euclidean Distance between the 
farthest pair of spots in two groups. The shorter dis-
tance between two spots/groups indicates more similar-
ity in their expression levels. A tree-shape diagram, or 
dendrogram, is typically used to illustrate the result of 
hierarchical clustering (lower panel in Fig. 2A). Third, Liu et al
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the dendrogram was used to further cluster scattered 
spots into fifteen subgroups   (containing N = 9, 8, 5, 4, 
11, 9, 33, 4, 3, 11, 10, 6, 17, 7 and 15 spots in fifteen 
subgroups, respectively). The lower part in   Figure 2A 
shows the array ID numbers labeled by rainbow col-
ors (a color per subgroup). We denoted the labels of 
subgroups for spots by variable Z (Z = 1–15). CID 
only used Z to represent the assigned subgroup of two 
co-expressed TFs. The same equation for   calculating 
both   univariate CID and bivariate CID was   performed 
except we replaced j by Z. The right panel in   Figure 2A 
describes the characteristics of ESR1 and E2F1 mRNA 
levels in each clustered   subgroup, where the height of 
the bar indicates a net value derived from the median of 
mRNA expression levels in each subgroup subtracted 
by global median of mRNA expression levels of ESR1 
and E2F1,   respectively. Thus, fifteen subgroups are 
represented  by  the  paired  color  bars,  respectively. 
In majority of ER (+) subgroups, low E2F1 mRNA 
  levels were   co-expressed with relatively high levels 
of ESR1 mRNA. We observed both ESR1 and E2F1 
mRNAs to be co-expressed at high level in three sub-
groups of ER(+) IDCs (see a heatmap in Fig. 9A and/
or a bar plot in Fig. 2A). In ER(-) group, however, all 
subgroups were having inverted expression pattern on 
E2F1 mRNA while comparing to ESR1 mRNA except 
one subgroup showing low E2F1 mRNA level. Final 
step is the CID evaluation on two TFs and their shared 
target genes that was taken place by the procedure 
previously described2 using the subgroup label, Z, as 
the predictor variable. In brief, CID-ESR1nE2F1 was 
resulted from the above analysis. Both Figures 2B 
and C show (1) a scatter plot of ESR1 mRNA level vs. a 
TF mRNA level; (2) the mRNA expression patterns of 
both ESR1 and a TF for 15 subgroups; (3) a dendrogam 
based on co-expressed ESR1 and a TF at mRNA level 
in 152A. A CID-ESR1nTF was also evaluated based on 
the same procedure described for E2F1 except that TF 
stands for GATA3 or ESRRA in this study.
Computing P-values for results  
from univariate CId, bivariate  
CId and gPCC analyses
We compute both univariate CID and bivariate CID 
using the same equation2 except the label of subgroups 
after hierarchical clustering were designated as j, z, 
respectively (see the method described above).
To access the significance of univariate or   bivariate 
CID  values  generated  via  in  silico  analyses  and 
to  facilitate  comparison  among  data  derived  from 
applying different types of methods, the univariate 
or bivariate CID value, S, was compared with the 
  values  generated  by  random  sampling  mimicking 
the mRNA expression data distribution of gene Y that 
is independent on the data partitioning of the assigned 
variable (a TF or TFs). In 152A study, the indepen-
dent  data  distribution  was  derived  from  randomly 
drawing 152 simulated values for an artificial gene 
and put appropriate number of data for the gene in 
each subgroup that is the same as the sample size in a 
pre-clustered subgroup. We re-computed the subCID 
value of each subgroup and added them together to be 
a new CID value (K). This was repeated 1,000 times 
and yielded 1,000 of CID values (Ki, i = 1–1,000). 
The  P  value  was  determined  by  an  equation  (i.e. 
P = (1+ N(ki  S))/1,001, where N(ki  S) is the number 
of Ki values greater than S). The P values for GPCC 
measurements were computed using asymptotic nor-
mal theory.11 We set the cut off point for P value of 
both methods to be significant when P # 0.05.
Finding biological implications  
of statistically identified gene pools
We used web-based software that helps in identifying 
the Gene Ontology and Pathway information for a gene 
list of interest. The web site is http://vortex.cs.wayne.
edu/projects.htm. The Gene Ontology tool is called 
“Onto-Express” and the gene annotation database is 
ontotools database. For pathway analysis, a method 
to gather all possible pathway information involving 
the gene list of interest is called “Pathway-Express”.12 
In addition, we also used commercial software called 
Gene Spring GX 7.3.1 (Agilent   Technologies, USA) 
in this study.
Results and Discussion
A flow chart of statistical analysis  
and the confounders controlled  
during multivariate analysis
Figure  1  briefly  describes  a  pictorial  sketch  of  the 
analysis steps used to carry out the statistical methods 
described above and indicates their predicted feature 
results to be demonstrated in figures “(see results and dis-
cussion below). The implementation of both   univariate Actions of transcription factors on shared target genes
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Univariate analysis Multivariate analysis
The mRNA levels
of TF1 in a
population
The mRNA levels
of TF2 in a
population
The mRNA levels
of TF1 or TF2 in
a population
The mRNA
levels of a
gene in a
population
GPCC
CID-TF1nTF2
(Figs. 3,5,7)
CID-TF1 or
CID-TF2
CID-TF1UGPCC or
CID-TF2UGPCC
Mechanism 1:
CID-TF1nTF2 (S)
CID-TF1UGPCC (S)
CID-TF2UGPCC (S)
Mechanism 2:
CID-TF1nTF2 (S)
CID-TF1UGPCC (S)
CID-TF2UGPCC (NS)
Mechanism 3:
CID-TF1nTF2 (S)
CID-TF1UGPCC (NS)
CID-TF2UGPCC (S)
Mechanism 4:
CID-TF1nTF2 (S)
CID-TF1UGPCC (NS)
CID-TF2UGPCC (NS)
The mRNA
levels of a
gene in a
population
Subgrouping by
one-dimensional
(TF1 or TF2)
hierarchical
clustering (Fig. 9)
Subgrouping by
two-dimensional
(TF1 and TF2)
hierarchical
clustering (Fig. 2)
Figure 1. Flow chart for genome-wide univariate and multivariate analyses. 
The  procedure  for  identification  of  a  statistically  relevant  promoter  use  pathway  and  its  regulatory  mechanisms  at  molecular  level  includes  (1) 
univariate analysis (left panel) of both linear association (e.g. gPCC) and non-linear association (e.g. univariate CId) of TF-target in a population; 
(2) multivariate analysis (right panel) of non-linear association (e.g. bivariate CId) of TF1nTF2-target in a population; (3) combined results from univariate 
and bivariate analyses to be divided into four categories. They are designated as mechanism 1, 2, 3 and 4, respectively.
and bivariate CID in R codes can be downloaded from 
http://homepage.ntu.edu.tw/∼lyliu/multCID/.
Statistically, the definition for confounders is for 
all variables that are unknown, not available or not of 
interest at this moment but affecting the systems. The 
same definition is also applied to biological systems.
In this study, we designed a few key steps to con-
trol confounders during multivariate analyses. They 
are as follows.
(1) We first selected two patient cohorts for mul-
tivariate analysis based on the statuses of immuno-
histochemical stains for ER and PR on their breast 
tumor sections (see Table S10); (2) We selected the 
active regulator—estrogen receptor alpha as the TF1 
because  its  aberrant  transcriptional  activities  have 
been observed in a large subset of breast   cancer; (3) We 
chose hierarchical clustering to facilitate in locating 
the potentially pre-programmed interaction pathway 
between  two  functionally  co-expressed  transcrip-
tion factors on their promoter use in a given cohort. 
Importantly, we picked up a target gene of TF1 to be 
TF2 in this study.13–16 As a result, such expression pat-
tern clustering strategy enhanced the ability of CID to 
identify a network of bivariate associations for both 
TF1 and TF2 to their shared target genes that in part 
validate a relevant event in vivo (see Fig. 8).
The predicted molecular features  
of a new multivariate analysis reveals 
the subtypic differences in their  
pre-programmed transcriptional 
regulation on three gene sets  
in a breast cancer population
The promoter content of statistically identified 
genes that are shared targets of two functional 
transcription factors
Firstly, we reasoned the structure/function relationship 
between transcription factors (e.g. TF1, TF2) and their 
binding sites on promoter regions of their shared target Liu et al
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Figure 2. The illustration for hierarchical clustering on two variables of interest. 
panel A. Upper left panel, a scatter plot for co-expression of ESR1 and E2F1 mRNAs in 152A. Fifteen clusters are labeled by a series of rainbow colors, 
respectively. The number of patients or N for 15 subgroups are presented in different color spots to be 9, 8, 5, 4, 11, 9, 33, 4, 3, 11, 10, 6, 17, 7 and 15, 
respectively. Upper right panel, paired bar plots showing the mRNA expression patterns of both ESR1 and E2F1 in each subgroup, respectively. Lower 
panel, a dendrogram indicating the fifteen subgroups labeled with their corresponding array ID number that was determined by hierarchical clustering. 
panel B. Upper left panel, a scatter plot for co-expression of ESR1 and GATA3 mRNAs in 152A. Fifteen clusters are labeled by a series of rainbow colors, 
respectively. The numbers of patients or N for 15 subgroups are presented in different color spots to be 3, 25, 16, 2, 7, 9, 3, 4, 8, 16, 9, 1, 13, 16 and 
18, respectively. Upper right panel, paired bar plots showing the mRNA expression patterns of both ESR1 and GATA3 in each subgroup, respectively. 
Lower panel, a dendrogram indicating the 15 subgroups labeled with their corresponding array Id number that was determined by hierarchical clustering. 
panel c. Upper left panel, a scatter plot for co-expression of ESR1 and ESRRA mRNAs in 152A. Fifteen clusters are labeled by a series of rainbow colors, 
respectively. The numbers of patients or N for 15 subgroups are presented in different color spots to be 3, 3, 17, 5, 6, 2, 20, 13, 11, 9, 13, 10, 26, 11 and 3, 
respectively. Upper right panel, paired bar plots showing the mRNA expression patterns of both ESR1 and ESRRA in each subgroup, respectively. Lower 
panel, a dendrogram indicating the 15 subgroups labeled with their corresponding array Id number that was determined by hierarchical clustering.
genes (Fig. 3) to be predicted via   bivariate CID. Thus, 
the gene expression relationship of co-  expressed TF1 
(e.g. ESR1) and TF2 (e.g. E2F1 or GATA3 or ESRRA) 
to their common target gene expression was measured 
by bivariate CID   (designated as CID-TF1nTF2). Sec-
ondly, we screened gene pools   statistically identified 
by CID-TF1nTF2 via their promoter contents pub-
lished by others.
We ran the bivariate CID on a dataset of 152A to 
measure gene expression relationship between (ESR1, 
E2F1) and their common target gene. As a result, 8,616 
probes were identified to be significant (P # 0.05) 
for CID-ESR1nE2F1. Only 194 probes among these 
8,616 probes are known to have E2F binding site(s)17 
(Table S3, Fig. 4). In addition, we identified 10,294 
probes via analysis of CID-ESR1nGATA3 in 152A. 
Only  102  probes  (102/10,294)  are  known  to  have 
both ER α and GATA binding site(s) at their promoter 
regions4 (Fig. 4). Finally, we identified 4,169 probes 
via analysis of CID-ESR1nESRRA in 152A. Only 
56 probes (56/4,169) are known to have both ERα 
and ERRα binding site(s) at their promoter regions.18 
Those gene sets were used to further predict for the 
combinatorial actions of their transcription factors on Actions of transcription factors on shared target genes
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1
TF1BS TF2BS TF1BS TF2BS
Differential activities of TF1 and
TF2 on Gene x mRNA expression
Differential activities of TF1
and TF2 on Gene x mRNA expression
CID-TF1UGPCC (S)
and
CID-TF2UGPCC (S) or (     )
and
NS
CID-TF1nTF2 (S)
Activated or suppressed
TF1 and TF2 transcriptional
complex (S)
Activated or suppressed
TF2 transcriptional
complex (NS) Activated or suppressed
TF1 and TF2 transcriptional
complex (S)
Activated or suppressed
TF1 and TF2 transcriptional
complex (NS)
CID-TF1UGPCC (     )
and
NS
NS CID-TF2UGPCC (S) or (     )
and
NS
CID-TF1nTF2 (S)
Mechanism (2)
Mechanism (1)
Mechanism (1)
Mechanism (2)
Mechanism (4)
Mechanism (4)
Mechanism (3)
Mechanism (3)
Gene x
Gene x
Gene x
Gene x
Gene x
Gene x
2
1 1
1 1 2
2
2 1
1 1
1
1 1 1
1
1
2
2
2 2
2
2 2 2
2
2 2
2
AB
Figure 3. Molecular model mechanisms of TF1 and TF2 on their shared target gene. The hypothesized transcriptional mechanisms for TF1 (also labeled 
as “1”), TF2 (also labeled as “2”) and target gene (labeled as “gene x”) are shown in panels A and B. They were predicted in silico by CId-TF1nTF2 along 
with both CId-TF1UgPCC and CId-TF2UgPCC (P # 0.05) (see Methods). The suppressive regulation on gene x mRNA expression is indicated by the 
blue solid arrow with a stop sign (x), which is located above the chromosomal dNA (black line). The increase mode on expression of gene x mRNA is 
indicated by the black solid arrow without a stop sign. TF1BS, TF2BS stand for the binding site of TF1, TF2, respectively. Current model for transcription 
factor families in regulating their target genes has been simplified in this figure based on the most updated literatures.5–10,33
notes: “S” stands for “significant”. “NS” stands for “not significant”.
regulating their gene expressions. We describe below 
how  both  univariate  and  multivariate  associations 
(i.e.  CID-TF1UGPCC,  CID-TF2UGPCC  and  CID-
  TF1nTF2) predict the features of functional promoter 
use pathway by two TFs of interest in a clinical breast 
cancer setting.
Statistical prediction on the mechanisms  
of promoter use for shared target genes by  
two TFs in group Ie breast cancer population
We defined statistically relevant mechanisms of the 
promoter use by both transcription factors of interest 
based on the hypothesis of ours. We hypothesized that 
the mRNA expression level of a gene, which contains 
both estrogen receptor binding site (ERBS) and E2F 
binding site (E2FBS) at the promoter region, would be 
dependent on either one or both functional transcription 
factors (e.g. ERα and E2F1) interacting with those cor-
responding binding sites. As a result, the differential 
activities of two transcription factors determine the final 
mRNA expression levels of their shared target genes, 
in part (Fig. 3). The same scheme was also applied in 
analyzing the mechanisms for ERα and GATA3, ERα 
and ERRα involved promoter use programs on their 
target genes, respectively.   Statistically, we further dis-
sected the promoter use features of identified genes 
by comparing results among the multivariate associa-
tion measured by bivariate CID (i.e. CID-TF1nTF2) 
and two univariate associations measured by coupling 
univariate CID (i.e. CID-TF1or CID-TF2) and GPCC. 
The statistically predicted results were partially vali-
dated via literature search.Liu et al
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CART model 2:
300 (EG)
CID-ESR1nGATA3
in group IE :10,294
ESR1 and ESRRA
overlapped
probes: 101
CID-ESR1nESRRA
in group IE: 4,169
IE_ESR1nESRRA
IIE_ESR1nESRRA IIE_ESR1nGATA3 IIE_ESR1nE2F1
IE_ESR1nGATA3 IE_ESR1nE2F1
E2F targets:
434
CID-ESR1nE2F1
in group IE: 8,616
Mechanism1
Mechanism 1
Mechanism 1
Mechanism 4 Mechanism 4 (3%)
(25%)
(14%)
(58%)
(16%)
(22%)
(43%)
(9%)
(47%)
(1%) (8%)
(4%) (66%)
(35%)
(38%)
(64%)
(18%)
(13%)
(5%)
(24%)
(3%)
(18%)
(8%)
(58%)
Mechanism 3 Mechanism 3
Mechanism 2 Mechanism 2
Mechanism 2
Mechanism 2
Mechanism 3
Mechanism 3
Mechanism 2
Mechanism 2
Mechanism 3
Mechanism 3
Mechanism 4 Mechanism 4
Mechanism 4
Mechanism 1
Mechanism 1
Mechanism 1
Mechanism 4
240 194 202 98  10,196  45  56 4,113 8,422
Figure 4. Summary of genes identified by bivariate CID and their pie distribution among four regulatory mechanisms in groups IE and IIE breast cancers. 
We performed dissecting transcriptional regulatory mechanisms in two TFs directed common target gene expressions by coupling the results derived 
from univariate associations (CID U GPCC) with those derived from bivariate CID in groups IE and IIE breast cancers. Upper panel, first, it represents 
one hundred ninety four probes (194 probes) identified significantly by CID-ESR1nE2F1 in group IE (8,616 probes). They belong to E2F targets (434 
probes) identified by others.17 Second, it represents one hundred and two probes (102 probes) identified significantly by both CID-ESR1nGATA3 in group 
IE (10,294 probes) and CART model 2 identified shared target genes of ERα and gATA3 (300 probes).4 Third, it represents fifty six probes identified sig-
nificantly by both CID-ESR1nESRRA in group IE (4,169 probes) and the overlapped target genes of ERα and eSRRA (101 probes).18 Lower panel shows 
subtype specific pie distribution of four regulatory mechanisms for 194, 102 and 56 probes, respectively.
Subgrouping of one hundred ninety four probes  
(194 probes) based on their gene regulatory  
mechanisms via differential interactions between  
eRα and e2F1 on their promoters
We summarized in Table S3 that 194 probes were 
selected  by  both  significance  in  multivariate 
association  (CID-ESR1nE2F1)  and  their  promoter 
content17  (i.e.  E2FBS)  in  group  IE  breast  cancer. 
They  were  further  analyzed  using  two  univariate 
measures of association (i.e. CID-ESR1UGPCC and 
CID-E2F1UGPCC). We claimed the target genes to 
be regulated via mechanism 1 through mechanism 4 
if CID-ESR1UGPCC and CID-E2F1UGPCC yielded 
results  of  (S,  S),  (S,  NS),  (NS,  S)  and  (NS,  NS), 
respectively, where S denotes significance and NS 
denotes   insignificance at significant level α = 0.05. 
They are listed in Table S1.
One hundred thirteen probes (113/194) were pre-
dicted to be regulated via mechanism 1 (Fig. 3 and 
Table S1) in group IE breast cancer. They were pre-
dicted in silico to be regulated by ERα, E2F1 alone 
(univariate association, P # 0.05). But, most impor-
tantly both transcription factors may cross talk to 
regulate this set of genes (multivariate association, 
P  #  0.05).  Nine  of  them  (9/113)  have  also  been 
identified in vitro by Bourdeau et al. (2008).19 They 
concluded  ASF1B,  BRIP1,  CDCA5,  RAD51AP1, 
SPBC25, TOP2A, UBE2T, CCNG2 and UBE2C to 
be estrogen responsive target genes. Table S3 shows 
twenty of them (20/113) having ERE site(s) at their Actions of transcription factors on shared target genes
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promoter  regions.20  Fourteen  of  them  (14/113) 
  follow indirect tethering mechanism.4 The detailed 
promoter uses by ERα and E2F1 either simultane-
ously or sequentially via mechanism 1still need to be 
validated in vitro.
Twenty seven probes (27/194) were predicted to 
be regulated via mechanism 2 (Fig. 3 and Table S1). 
Those probes were predicted statistically relevant to 
be preferentially regulated by ERα in vivo but not 
to be significantly regulated by E2F1. Only CD44 
(1/27) was documented to have ERE site at its pro-
moter region20 and RNF130 follows indirect tethering 
mechanism of classical ER pathway.4 The remaining 
twenty five probes (25/27) may follow ERE indepen-
dent ER pathways to be preferentially regulated by 
ERα, while their E2FBS were not statistically rel-
evant in functional interacting with E2F1 that was 
predicted by univariate CID and/or GPCC (P . 0.05) 
(Fig. 3, Tables S1 and S3). But, when both TFs are 
co-expressed  in  tumor  section,  either  sequentially 
or  simultaneously  cross  talking  between  ERα  and 
E2F1 may take place (CID-ESR1nE2F1, P # 0.05) 
(Table S1). These potential mechanisms are awaited 
to be proved in vitro.
Forty eight probes (48/194) have been identified 
in group IE breast cancer to be significantly regulated 
by mechanism 3 (Fig. 3 and Table S1). It indicates the 
promoter use by both ERα and E2F1 to the promoter 
regions  of  those  probes  via  mechanism  3  to  be  a 
statistically relevant event in group IE breast cancer 
(CID-ESR1nE2F1, P # 0.05). In addition, a gene being 
expressed via this mechanism is predicted to partially 
contributed  by  the  functional  interaction  between 
E2F1 and E2FBS alone (CID-E2F1UGPCC). However, 
ERα alone may have a limited contribution for such 
regulatory  mechanism.  No  statistically  significant 
regulatory event for these genes was predicted to be 
regulated  by  ERα  (CID-ESR1UGPCC,  P  .  0.05). 
For example, only ATAD2 was found to be an estrogen 
responsive  target  gene.19  It  has  both  ERBS20  and 
E2FBS17 at its promoter region. However, its promoter 
use by ERα and E2F1 follows mechanism 3 in group 
IE breast cancer. Interestingly, seven of them (7/48) 
have known ERE sites20 (Table S3). Three of them 
(3/48) are known to be regulated via indirect tethering 
mechanism of classical ER pathway.4 The predicted 
regulatory mechanism of those probes still need to be 
validated in vitro.
Six (6/194) probes were predicted to be regulated 
by both ERα and E2F1via mechanism 4 (Fig. 3 and 
Table S1), which suggests solely an ERα and E2F1 
cooperative  regulation  on  those  gene  expressions. 
Only SFRS1 (1/6) has both ERBS20 and E2FBS17 sites. 
The remaining probes (5/6) have E2FBS17 sites but no 
validated ERBS. Thus, it indicates two types of ERα 
pathways, classical and non-classical ones, together 
with E2F1 to allow transcriptional regulation on their 
target gene expression via mechanism 4 in group IE 
breast cancer population. However, further evidence 
in vitro would be needed to support this prediction.
Sixteen  (16/194)  probes  have  more  than  one 
mRNA products, which have been indicated by their 
unique  feature  numbers. There  are  mRNA  expres-
sions of seven pair variants following the same mech-
anism (i.e. AGGF1, DZIP3, H2AFX, KHSRP, PLDN, 
RAD54B and TRAIP). But for SP1 transcript variants, 
their expressions follow different mechanisms of pro-
moter use, which are via differential interactions of 
ERα and E2F1 on promoter region of SP1 (Table S1). 
Those  mechanisms,  which  indicate  the  possible 
switching in promoter use for two TFs in regulating 
the expression of transcript variants, are awaited to be 
validated by well defined experiments in vitro.
Subgrouping one hundred and two probes (102 probes) 
based on their gene regulatory mechanisms via differential 
interactions between eRα and gATA3 on their promoters
102 probes, which are known to have both ERBS and 
GATA3  binding  site  (GATABS)  in  their  promoter 
regions,4  were  detected  to  be  significant  by  CID-
ESR1nGATA3 in 152A (Fig. 4, Tables S4 and S6). 
  Further dissecting the relevant transcriptional activi-
ties involving both TFs, we concluded four mecha-
nisms either simultaneously or sequentially regulating 
those gene expressions at mRNA level. Those tar-
get genes were claimed to be regulated by ERα and 
GATA3 via mechanism 1 through mechanism 4 based 
on the same definition described for the combinatorial 
interaction between ESR1 and E2F1 to the promoter 
region of their common target gene.
We summarized the predicted regulatory mecha-
nisms among those probes following ESR1_GATA3 
pathway  as  follows. There  were  fifty  nine  probes 
(59/102) to be regulated via mechanism 1 (Table S4). 
Sixteen of them (16/102) were identified to be reg-
ulated  by  mechanism  2.  Nineteen  (19/102)  were Liu et al
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  regulated  via  mechanism  3.  Eight  (8/102)  were 
regulated  via  mechanism  4.  Two  genes  (4/102)—
EVX1 and SLC9A3R1 were identified to share the 
same mechanism in their transcript variant expres-
sions  (i.e.  both  transcriptional  and  post-transcrip-
tional  regulation)  involving  actions  of  ERα  and 
GATA3 on their promoter regions. Moreover, two 
transcript variants of a gene (2/102)—IGFBP5 were 
regulated by ERα and GATA3 via different promoter 
use   mechanisms. Only 12 probes (12/102) were doc-
umented to have ERE sites20 (Table S6). Therefore, 
it would be highly desirable for one in finding more 
supporting   evidence in vitro  for  those  statistically 
relavant regulatory mechanisms.
Subgrouping fifty six probes (56 probes) based on their 
gene regulatory mechanisms via differential interactions 
between eRα and eSRRA on their promoters
ERRα  (or  ESRRA)  does  not  respond  to  estrogen 
stimuli in general. However, its ligands are recently 
listed  to  be  isoflavones,  chlordane  and  diethylstil-
bestrol  (DES).21 The  activity  of  ERRα  is  strongly 
stimulated by the co-expression of coactivators with-
out adding a ligand.22 Moreover, ERRα is evolution-
arily related to estrogen receptors and can efficiently 
bind to EREs.23 We selected a gene list (101 probes) 
as estrogen induced and shared target genes of both 
ERα and ERRα from the gene expression data of an 
estrogen responsive breast cancer cell line (MCF7). 
Their transcription factor binding sites for ERα and 
ERRα have been validated in vitro.18 Only 56 probes 
(56/101) were overlapped with the shared target gene 
pool of both ESR1 and ESRRA in 152A that were pre-
dicted by bivariate CID (Fig. 4).
Thirty six of them (36/56) indicate the regulatory 
mechanism as mechanism 1 (Table 1). Six of them 
(6/36) have ERE sites20 (Table S9). One among those 
6 probes—DDIT4 not only has an ERE site20 at pro-
moter region but has been documented to be possibly 
regulated  following  indirect  tethering  mechanism.4 
Six of them (6/36) could be regulated following teth-
ering mechanism4 (Table S9).
Ten  probes  (10/56)  were  predicted  to  be  regu-
lated by ESR1 and ESRRA via mechanism 2. Only 
LMO4(17053)  (1/10)  may  be  regulated  not  only 
by  mechanism  2  of  ESR1_ESRRA  promoter  use 
pathway  but  by  tethering  mechanism.4  Seven 
probes  (7/56)  were  predicted  to  be  significant  for 
  mechanism 3. However, only EFNA1 (1/7) has an 
ERE site20 at its promoter region. In addition, SYP 
(1/7)  follows  tethering  mechanism.4  We  observed 
three probes (3/56) to be possibly regulated via mech-
anism 4 in group IE breast cancer. PTMA (1/3) has 
been found to have an ERE site.19
In  summary,  there  is  a  trend  for  three  sets  of 
gene  expressions  at  mRNA  level  to  be  potentially 
regulated  by  their  transcription  factors  shown  in 
Figure 4. Majority of probes (58% for ESR1_E2F1 
pathway;  58%  for  ESR1_GATA3  pathway;  64% 
for ESR1_ESRRA pathway) are predicted to follow 
mechanism 1(Figs. 4–6). The number of probes being 
regulated via mechanisms 2, 3 and 4, are less than those 
via mechanism 1. The mixed mechanism (i.e. Two TFs 
regulate the expression of a target gene which has more 
than one mRNA products.) is the rare case that may 
involve  both  transcriptional  and  post-transcriptional 
regulatory  event.  In  addition,  both  promoter  use 
pathways and regulatory mechanisms in each pathway 
in regulating three gene sets are quite different between 
groups IE and IIE (Tables S2, S5 and S8).
The role of bivariate CId in multivariate 
space of a transcriptional regulatory 
network and its predicted subtypic 
difference in response to pre-
programmed promoter use pathways 
upon estrogen exposure
We hypothesized that the mRNA expression level of a 
gene, which contains binding sites for both functional 
TFs at its promoter region, would depend on either 
one or both TFs interacting with those correspond-
ing binding sites to initiate its gene expression. As a 
result, we briefly illustrated the statistically relevant 
mechanisms of the promoter use by both transcrip-
tion factors in determining the final mRNA expres-
sion levels of their shared target genes (Fig. 3). This 
scheme was applied in analyzing the mechanisms for 
ERα_E2F1, ERα_GATA3 and ERα_ ERRα involved 
promoter uses on their target genes in a given breast 
cancer population (Tables S1, S4 and S7).
Four  statistical  conclusions  derived  from  three 
statistical  measures  (i.e.  CID-TF1nTF2,  CID-
TF1UGPCC  and  CID-TF2UGPCC)  were  grouped 
into four proposed biological regulatory pathways, 
respectively  (Figs.  3–6).  It  indicates  a  preferential Actions of transcription factors on shared target genes
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Table 1. Summarized statistical analyses of 56 probes on their gene expression regulatory mechanisms by both eRα and 
gATA3. 
probe no Featurenum Genename esR1 esRRA esR1esRRA Mechanism
1 16378 ANKMy2 S S S 1
2 8540 ATP1B1 S S S 1
3 1487 ATP6AP2 S S S 1
4 10261 ATP6V0A1 S S S 1
5 13294 C6orf211 S S S 1
6 15121 CA12 S S S 1
7 18269 CALU S S S 1
8 12896 CASd1 S S S 1
9 3580 CSAd S S S 1
10 2085 CyCS S S S 1
11 11758 ddIT4 S S S 1
12 18926 dhRS3 S S S 1
13 12004 eNo1 S S S 1
14 5480 eSRRA S S S 1
15 7339 FAM100A S S S 1
16 1034 FAM102A S S S 1
17 13981 FRAT2 S S S 1
18 14967 gATA3 S S S 1
19 16477 KCNN4 S S S 1
20 13712 KIAA0664 S S S 1
21 19715 KRT18 S S S 1
22 20526 LeTMd1 S S S 1
23 8255 LMo4 S S S 1
24 15258 LSMd1 S S S 1
25 11537 MRPS30 S S S 1
26 14171 MyBPC3 S S S 1
27 2111 NdUFA11 S S S 1
28 11771 PCyT1A S S S 1
29 1098 PFN1 S S S 1
30 19493 PLCd3 S S S 1
31 19203 PReX1 S S S 1
32 6791 PTP4A2 S S S 1
33 6795 STeAP3 S S S 1
34 9377 TBKBP1 S S S 1
35 11917 WWP1 S S S 1
36 12247 ZBTB20 S S S 1
37 12023 C11orf21 S NS S 2
38 383 CoQ7 S NS S 2
39 17802 FdXR S NS S 2
40 21403 gPd1 L S NS S 2
41 17053 LMo4 S NS S 2
42 2749 MCM6 S NS S 2
43 17911 NyX S NS S 2
44 3707 PgPeP1 S NS S 2
45 10567 PIK3AP1 S NS S 2
46 8719 TARS S NS S 2
47 1409 C6orf62 NS S S 3
48 12111 eFNA1 NS S S 3
49 12417 MRPL34 NS S S 3
50 1636 NdRg4 NS S S 3
51 6418 SULT2B1 NS S S 3
52 9539 SyP NS S S 3
52 13484 TySNd1 NS S S 3
54 6397 PhF15 NS NS S 4
55 11333 PhF8 NS NS S 4
56 4335 PTMA NS NS S 4
note: “S” means “significant” and “NS” means “not significant”.Liu et al
124  Cancer Informatics 2012:11
6002TS-CIN-1100-2012
TF2 TF2
TF2
TF2
TF2
TF1
TF1
TF1
TF1
TF1
TF1
TF1
Target gene X
Target gene X
Target gene X Target gene X
TF1 TF2
TF1
Multivariate association−mechanism 3 Multivariate association−mechanism 4
Multivariate association−mechanism 2 Multivariate association−mechanism 1
Figure 5. The distinctive combinations of regulatory relationships for four functional gene expression relationships between (TF1, TF2) and target gene X. 
Univariate association measured by both CId and gPCC is to predict direct (a) and/or remote (b) regulatory relationships between a TF and a gene of 
interest (i.e. TF1→TF2, TF2→ target gene X and TF1→ target gene X). For case (a), TF2 is known a primary target gene of TF1. In the meantime, target 
gene X is known as a primary target of TF2. Moreover, TF1 is a transcription factor of target gene X. For case (b), TF2 is a remote target of TF1. Target 
gene X is a remote target of TF2. In addition, target gene X is a remote target of TF1. on the other hand, multivariate association includes (1) multivariate 
association partially dependent of univariate association (i.e. mechanisms 1, 2 and 3); (2) multivariate association independent of univariate associa-
tion (i.e. mechanism 4). The individual mechanism is demonstrated by the regulatory association derived from functional interactions of TF1, TF2 at the 
promoter region of target gene X. As a result, it is clear that our findings in Tables 1 and 2 have included estrogen responsive genes which have been 
discussed in main text. This indicates that bivariate CId in general measures direct and/or remote associations between co-expressed TF1, TF2 and 
their shared target genes. however, these regulatory mechanisms occurring either simultaneously or sequentially can not be distinguished through this 
approach. Red solid curve with arrow stands for a regulatory relationship between TF1 and target gene X. Black solid arrows stand for the basic regula-
tory relationship of a TF and its target gene or of TF1_TF2 and their shared target genes. dashed yellow-green curve stands for position switching of TF1 
to join with TF2. Five basic regulatory interactions are predicted via this approach. They are (1) TF1 directly regulates TF2; (2) TF1 indirectly regulates 
target gene X via TF2; (3) TF1 may also simultaneously join TF2 to co-regulate target gene X; (4) TF1 regulates target gene X; (5) TF2 regulates target 
gene X. As such, they become four small networks further demonstrating four types of interactions between TF1 and TF2 (or four transcriptional regulatory 
mechanisms) in controlling the expression of gene X.
promoter use via mechanisms 1, 2, 3 and 4 by two 
functional transcription factors on their shared target 
genes  in  a  breast  cancer  population  that  can  be 
statistically  identified.  Whether  the  transcriptional 
program is simultaneously or sequentially involving 
two TFs, its mechanism remains unclear based on this 
  prediction. For instance, 302 probes were expressed 
due  to  the  pre-programmed  estrogen  effects  on 
estrogen  responsive  gene  expression  in  MCF-7  as 
Increase,  Increase,  Increase  in  a  time  dependent 
  manner  (III  mode)  (Table  S11).  Only  six  probes 
(6/302) with such expression mode were predicted 
to stimulate cell cycle signal transduction pathway 
(Table S12). Eight (8/302) probes were also predicted 
to be regulated by ERα_E2F1 pathway in group IE 
subtype via   mechanisms 1, 2 and 3 (Table S13). Both 
ATAD2  and  DTL  have  been  identified  in  estrogen 
responsive  event19  in  vitro.  Our  data  suggests  that 
group IE breast cancer showed the suppressive effect 
on E2F1 gene expression at mRNA level by ESR1 Actions of transcription factors on shared target genes
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Figure 6. distinctive features of a shared target gene pool of both TF1 
and TF2 based on their overlapped and non-overlapped genes with target 
genes of TF1 and/or of TF2. They were divided into four categories. We 
designated them to be mechanism 1, 2, 3 and 4, respectively.
Mechanism 1: the feature definition for mechanism 1 is a target gene 
expression via cross talking between TF1 and TF2 that is significantly 
identified by the bivariate CID. In addition, the identified gene expres-
sion relationship of TF1_TF2 and their shared target genes partially is 
dependent on individual regulatory action of TF1and TF2 on their shared 
target gene, respectively. however, this event occurring simultaneously 
or  sequentially  can  not  be  distinguished.  Mechanism  2:  the  feature 
definition for mechanism 2 is a target gene expression via cross talking 
between TF1 and TF2 that is significantly identified by the bivariate CID. 
In addition, the identified gene expression relationship of TF1_TF2 and 
their shared target gene is also partially involved the regulatory action 
of TF1 on their shared target gene. however, this event occurring simul-
taneously or sequentially can not be distinguished. Mechanism 3: the 
feature definition for mechanism 3 is a target gene expression via cross 
talking between TF1 and TF2 that is significantly identified by the bivariate 
CID. In addition, the identified gene expression relationship of TF1_TF2 
and  their  shared  target  gene  partially  is  dependent  on  the  regulatory 
action of TF2 on their shared target gene. however, this event occurring 
simultaneously or sequentially can not be distinguished. Mechanism 4: 
the feature definition for mechanism 4 is a target gene expression via 
cross talking between TF1 and TF2 that is significantly identified by the 
bivariate CID. In addition, the identified gene expression relationship of 
TF1_TF2 and their shared target genes is independent on the individual 
regulatory actions of both TF1 and TF2 on their target gene. however, this 
event occurring simultaneously or sequentially can not be distinguished. 
Three circles represent three statistical measures. The open circles filled 
with light yellow and light blue colors stand for significance when the 
regulatory association is measured by univariate association (i.e. CId-
TF1UgPCC; CId-TF2UgPCC, P # 0.05), respectively. The open circle 
filled with dark green color stands for significance when the regulatory 
association is measured by multivariate association (i.e. CId-TF1nTF2, 
P # 0.05). The overlapped area between multivariate association and 
univariate association(s) represents functional mechanisms 1, 2 and 3. 
Functional mechanism 4 shows the area only for multivariate association 
but no overlapping area between multivariate association and two univari-
ate associations.
in general (Fig. 9A). As a result, both expression of 
CD44  and  IVNS1ABP  were  suppressed  at  mRNA 
level (see GPCC-ESR1 results for ESR1 vs. CD44 and 
ESR1 vs. IVNS1ABP in Table S13) via mechanism 
2 in group IE breast cancer. RACGAP1, RFC3 and 
YBX1 were predicted to be down regulated by ERα 
and  E2F1via  mechanism  1.  However,  ALG8  was 
found to be up-regulated in group IE breast cancer 
(see GPCC-ESR1 result for ESR1 vs. ALG8 in Table 
S13) via mechanism 2 and in estrogen treated MCF-7. 
In the meantime, bivariate CID predicted five genes 
in III mode to be differentially co-regulated by ESR1 
and GATA3. CCT5 and GART were possibly down 
regulated via mechanism 1. Both DHFR and KPNB1 
were predicted to be up regulated via mechanisms 
1 and 3, respectively. CPSF2 was predicted to be down 
regulated via mechanism 3. Furthermore, KIF2C and 
CDCA8 are two shared target genes of ERα, E2F1 and 
GATA3. They have ERE,20 E2FBS17 and GATA3BS4 
at their promoter regions. They were predicted to be 
significantly regulated via both ESR1_E2F1 and ESR1_
GATA3 promoter use pathways in group IE subtype 
(Tables S1 and S4). Therefore, we suspected that their 
mRNA expression mode may be operated by switching 
promoter  use  pathways  and/or  switching  regulatory 
mechanisms under a pre-programmed condition. Thus, 
by gathering these predicted mechanisms, it would be 
worth to further prove the switching mechanism of III 
mode to a suppressive mode, in part, due to alternative 
promoter  use  by  different  interactions  among  TFs 
in a time dependent manner to achieve a particular 
phenotype in the model systems.
An inferred transcriptional regulatory 
network and future medicine
our experience in a microarray approach
In silico established ERα transcriptional regulatory 
network predicts a global effect of functional ERα 
alone  (univariate  portion  of  network)  and  of  ERα 
and TF(s) (multivariate portion of network). Here, 
we  use  breast  cancer  functional  transcriptome  to 
briefly test how ERα regulates its target genes in an 
estrogen-dependent manner. In particular, we propose 
the network to predict that ERα interacts with differ-
ent transcription factors to achieve gene expression 
responses in the subgroup of patients with breast can-
cer who were diagnosed with a pathological feature of 
interest. Multiple signaling pathways are known to be 
activated by functional ERα. We observed the altered 
mRNA expression patterns for three signal transduc-
tion pathways in groups IE and IIE breast tumors as 
compared to those in non-tumor part in the heatmap 
generated  by  unsupervised  hierarchical  clustering 
(Figs. S1, S2 and S3). They are cell cycle, VEGF Liu et al
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Figure 7. The simplified model of co-regulatory networks predicted by multivariate CID. 
An example of eRα initiated transcriptional co-regulatory network is illustrated. When eRα interacts with other TF(s) to co-regulate a gene pool, some 
of those target genes (e.g. y1, y2) may have more than one type of binding site (TFBS) at their promoter regions to permit cross-talk among eRα, TF1, 
TF2 and TFK. As a result, different clusters of gene pools indicated in the figure show their gene expression relationships with the assigned TFs due to a 
preference in promoter use pathways (i.e. I, II, III). While comparing 194 probes with 102 probes in this study, only KIF2C, CDCA8 were found to be the 
shared targets of eRα, gATA3 and e2F1 both in vitro and in silico (see Tables S1 and S4). green solid arrows stand for the causal regulatory relationship 
of a TF and its target gene or of more than one TF and their shared target genes. dashed green curve stands for position switching of eRα. The combinato-
rial regulatory interactions between or among eRα and TFK (K = 1, 2, 3, k . 3) are indicated in the figure that eRα either directly regulates TFK or indirectly 
regulates target gene (X, y, Z) via TFK or eRα may also simultaneously join TFK to regulate their target genes (e.g. X1 … n, y1 … n, Z1 … n).
and  PDGFRB  signal  transduction  pathways. Then, 
we suspected coregulatory networks of ESR1_E2F1, 
ESR1_ESRRA  and  ESR1_GATA3  in  group  IE  to 
have  their  overlapped  target  gene  pools  that  dif-
ferentially  contribute  to  those  signal  transduction 
pathways,  respectively.  The  combined  interactions 
among ESR1, E2F1, ESRRA and GATA3 to regulate 
their shared target gene pools were demonstrated by 
Venn Diagrams (Tables S18, S20 and S22). We have 
summarized in Table 2 for ERα mediated transcrip-
tion activities via combinatorial interactions between 
or among transcription factors in groups IE and IIE 
to potentially contribute to three signal transduction 
pathways. Interestingly, we validated this multivariate 
portion of network to be functionally linked to a clini-
cal  pathological  phenotype  (i.e.  Vascularity  index) 
in a subset of patients. This suggests its predicting 
power in dissecting the regulator(s) of disease pheno-
typic features through functional interactions among 
transcription factors (Fig. 8). In addition, the inferred 
network  (Fig.  8B)  shows  that  groups  IE  and  IIE 
shared most of promoter use pathways except for an 
Table 2. The numbers of probes in gene pools of cell cycle, VegF and PdgFRB signal transduction pathways to be regu-
lated by eSR1_e2F1 (ee1), eSR1_gATA3 (eg), eSR1_eSRRA (eeSRRA) as well as by their combined promoter use 
pathways in groups Ie and IIe breast cancers.
promoter use pathway 
eR(+) subtypes
ee1 eG eesRRA ee1_eG_ eesRRA
Ie IIe Ie IIe Ie IIe Ie IIe
Cell cycle (128 probes) 71 62 76 46 62 43 44 17
VegF (110 probes) 27 30 63 34 52 25 17 7
PdgFRB (65 probes) 26 18 41 16 26 17 17 6
note: For biochemical pathway profiling of a transcriptional regulatory network, we included the signal transduction pathways from both KEGG database 
and NCBI pathway interaction database.Actions of transcription factors on shared target genes
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Figure 8. An example of tumor angiogenesis activities in part co-driven by eSR1_e2F1, eSR1_gATA3 and eSR1_eSRRA promoter use pathways in a 
few eR(+) breast cancer patients. 
The vascularity index is a clinical parameter—a new measure for angiogenesis activities using ultrasound that now is routinely used clinically. Panel A 
shows the heatmaps of a gene profile in a network, which is shown in Panel B, for both groups IE and IIE breast cancer patients. Non-tumor part (NT) 
is a control. Panel B shows shared multivariate space of a network in two eR(+) breast cancer subtypes except E2F1 is only significantly regulated by 
eSR1_gATA3 pathway in group Ie breast cancer. Panel C shows the corresponding sonograms for each breast tumor piece per patient array Id. A labeled 
VEGFA (&) has the Agilent feature number as 15367.
ESR1_GATA3 pathway to indirectly regulate VEGFA 
and PDGFRB via E2F1. Both VEGFA and PDGFRB 
are functionally related to tumor vascularity.24,25
Tumor angiogenesis is required for tumor out-
growth and metastasis. It is a complex and highly 
regulated  process  involving  many  different  cell 
types and extracellular factors. PDGF receptor beta 
staining was particularly localized in the cell sur-
face membrane portion of periepithelial stroma in 
breast carcinoma, suggesting a paracrine stimulation 
of adjacent stromal tissue by breast tumor cells.26 
Interestingly,  the  statistical  correlation  between 
high level of estrogen receptor protein expression 
and the presence of PDGFR beta protein in cyto-
plasmic  compartment  was  found  in  24%  (6/25) 
breast  cancer  specimens.26  This  may  support  our 
network prediction. In addition, the promoter con-
text of both VEGF (ERE,27,28 E2F29 and Sp129) and 
  PDGFRB30 (NF-Y, AP-1, Sp1) also supports network 
  prediction (i.e. direct and/or indirect regulations on 
gene expressions of VEGF and PDGFRB by differ-
ential interactions among ESR1, E2F1, GATA3 and 
ESRRA). VEGFA is known to be a druggable target 
for anticancer treatment.
For  a  population  with  similar  expression  ratios 
between two co-expressed TFs to be grouped together 
(roughly N = 10), we assumed that those TFs may 
operate their interactions to a similar extent. In this 
case,  a  hierarchical  clustering  was  applied  to  per-
form  subgrouping. As  such,  if  the  association  for 
TF1nTF2-target gene measured by bivariate CID is 
significant, we could easily locate a subgroup with 
high subCID value in a given population to show 
more contribution for such relationship.   Theoretically, 
a  network  was  built  by  linking  together  multiple 
significant  TF1nTF2-target  relationships.  To  over-
all evaluate a functional network in a given popula-
tion, a supervised heatmap (A dendrogram at X axis) 
will show the gene expression pattern of a network 
component (i.e. a probe) to be clustered following a 
preclustered order of TF(s) (that is exactly the same 
order shown in a dendrogram) (Fig. 9). For instance, 
eight genes in EE1 pathway following mechanisms 1, 
2, 3 and 4 are shown in a heatmap for 152A (Fig. 9B). Liu et al
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Figure 9. (Continued)
The heatmap with unsupervised clustering on those 
genes is as the control.
In silico established transcriptional regulatory net-
work  approach  demonstrates  a  qualitative  measure 
for predicting cause/result relationships between TFn 
(n $ 1) and target. Therefore, a range of expression 
levels from low to high for gene components within 
this network is expected. Some of them are expressed 
in a pattern as a cluster shown in a heatmap based on 
their  similarity  in  expression  levels  in  several  sub-
groups (Fig. 9A). Many of them are expressed in a 
scatter pattern shown in a heatmap (Fig. 9B). When 
the  suppressive  mode  of  ERα  on  E2F1  expres-
sion becomes weak, E2F1 mRNA level is increased 
(Fig. 9). Some of those genes in cell cycle signal trans-
duction pathway are switched to an increased mode 
same as E2F1. We picked four significant probes as the 
example and displayed them in a heatmap (Fig. 9A). 
They were predicted to have more direct control in TF-
target relationship (Significance in linear relationship 
evaluated by GPCC analysis, see Table S14) and less 
remote control in TF-target relationship (Significance 
in nonlinear relationship evaluated by CID analysis, 
see Table S14). But all of them were significant based 
on  bivariate  CID  analysis  (Table  S14).  We  found 
in vitro evidence showing three of them (3/8) to have 
both E2F1 and ERα binding sites (Table S3). They are 
ADAMTS5, CD44 and SFRS1. We also observed only 
two subgroups in 152A to have high mRNA levels of 
both ESR1 and E2F1. They showed 8 tested probes to 
form the clustered gene expression pattern in a heat-
map (Fig. 9B). In Figure 9, we demonstrated the fea-
ture of CID in picking up the most relevant probes 
(P = 0–0.05). The gene expression patterns of those 
probes show either clustered or scattered patterns in a 
heatmap. The display of a heatmap follows two dimen-
sionally supervised (X axis represents an order of a 
Dendrogram; Y axis represents an order of assigned 
gene  list)  but  unsupervised  clustering  made  within 
each subgroup. Such heatmap display indicates that 
the enriched target gene expression pattern shown in 
the heatmap may allow a clear vision on linking them 
with the transcription regulator(s) to form a functional 
subnetwork. Further supporting information will prove 
this approach to be powerful. For instance, in vitro 
and/or in vivo validations on the novel relationship(s)   Actions of transcription factors on shared target genes
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Figure 9. Two examples of cumulative distribution function (CdF) estimation plots for target genes co-driven by eSR1_e2F1 promoter use pathway in 
152A and their corresponding heatmaps.
panel A. Three sets of CdF plots and heatmaps for four shared target probes of both ESR1 and E2F1 in cell cycle signal transduction pathway. Upper 
panel shows the display of a heatmap supervised with a dendrogram for ESR1 (left) and the CdF plots of CId-eSR1 measurements on probes of inter-
est (right). Middle panel shows the display of a heatmap supervised with a dendrogram for e2F1 (left) and the CdF plots of CId-e2F1 measurements 
on probes of interest (right). Lower panel shows the display of a heatmap supervised with a dendrogram for co-expressed eSR1 and e2F1 (left) and the 
CdF plots of CId-eSR1ne2F1 measurements on probes of interest (right). The bivariate CId predicts 4 probes (CCNB2, CDC14 A, CUL1 and SMC1B) to 
be regulated by ESR1 and E2F1. Fifteen subCId values are listed in a CdF plot per tested probe. This includes two univariate associations (CId-eSR1, 
CId-e2F1) and one multivariate association (CId-eSR1ne2F1). A heatmap of six probes based on unsupervised clustering is as a control. Fifteen sub-
heatmaps are displayed side by side to form a heatmap that was supervised with its corresponding dendrogram showing a simple, powerful visualization 
for the regulatory effect of ESR1 and/or E2F1 on four target gene expression patterns when each heatmap is compared to the control. panel B. Three 
sets of CdF plots and heatmaps for eight shared target probes of both ESR1 and E2F1. Upper panel shows the display of a heatmap supervised with a 
dendrogram for eSR1 (left) and the CdF plots of CId-eSR1 measurements on probes of interest (right). Middle panel shows the display of a heatmap 
supervised with a dendrogram for e2F1 (left) and the CdF plots of CId-e2F1 measurements on probes of interest (right). Lower panel shows the display 
of a heatmap supervised with a dendrogram for co-expressed eSR1 and e2F1 (left) and the CdF plots of CId-eSR1ne2F1 measurements (right). 8 
probes were predicted to be regulated by ESR1 and E2F1 following mechanisms 1 (two variants AGGF1), 2 (BUB3, CD44), 3 (ACTR10, ADAMTS5) 
and 4 (CNOT4, SFRS1) by bivariate CId. Fifteen subCId values are listed in a CdF plot per tested probe. This includes two univariate associations 
(CId-eSR1, CId-e2F1) and one multivariate association (CId-eSR1ne2F1). A heatmap of eight probes generated based on unsupervised clustering is 
as a control. Fifteen subheatmaps are displayed side by side to form a heatmap that was supervised with its corresponding dendrogram show a simple, 
powerful visualization for the regulatory effect of ESR1 and/or E2F1 on eight target gene expression patterns when each heatmap is compared to the 
control. The Agilent feature number for each probe is within a parenthesis right behind its corresponding gene name shown in CdF plots of panel A and 
panel B. Those color bars underneath the heatmap are used to label each subgroup which was clustered by hierarchical clustering.
in network(s) will be needed. To link network with 
phenotypic changes, to further validate a subnetwork 
to be essential to a particular pathological state etc. are 
a few experimental directions in adding our knowledge 
for how transcriptional dynamics between or among 
transcriptional regulatory subnetworks in determining 
tumor fate. Our ongoing effort in discovering drugga-
ble targets as well as prognostic factors with network 
approach has been encouraging. It is becoming clear 
that we may unravel the action of a transcription factor 
in coupling with its major partner transcription factor(s) 
at a system-wide scale with network approach.Liu et al
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The potential technical concerns in interpreting 
results from network approach
In  silico  established  transcriptional  regulatory  net-
work, which can be built via a series of unbiased 
analyses  using  appropriate  algorithms,  enables  us 
in dissecting complex disease biology. Here, a few 
technical concerns are concluded based on our expe-
rience in using in silico built transcriptional regula-
tory network constructed mainly by CID in a clinical 
breast cancer model system. Most of them may be 
from the shortcomings of high throughput biology 
and the heterogeneity of disease. But, only a few are 
from   network approach.
(1)    When one only measures the association between 
or among continuous variables using hierarchi-
cal clustering for subgrouping, a few results are 
not similar to subgrouping via expression levels 
in  dichotomous  or  multichotomous  categories 
(e.g.s  immunohistochemical  staining),  which  is 
more relevant to clinical status. For instance, the 
bivariate CID measurement for ESR1_TFx-target 
may provide the result to be less relevant than that 
for ERα_TFx-target. ESR1/TFx mRNA ratio may 
not truly reflect protein ratio for ERα/TFx because 
Jarzabek et al.31 concluded that the gene expres-
sion of ESR1 at mRNA and protein levels are not 
in a linear relationship in breast cancer due to 
post-transcriptional or post-translational mecha-
nisms. In some cases, ERα is more dysregulated 
in breast cancer. But, the TF of interest may be 
more tightly regulated in breast cancer. As such, 
more supporting experiments will be performed 
to validate prediction from network approach.
(2)    This network architecture is highly dependent on 
the content of a given population. When dealing 
with heterogeneous disease like cancer, this network 
approach  may  conclude  the  functional  relevant 
phenotype(s) to be significant and to be reproduc-
ible only if the population has been well selected.
(3)    A small bias in P value determination between 
two different runs for the same experiment can not 
be avoided. This is due to random sampling dur-
ing 1,000 times simulations per experiment may 
alter the chance of a few probes to be recruited as 
the significant ones.
(4)    The limitation in sampling options for clinical sam-
ples (a sample per patient and this sample is a por-
tion of tumor tissue not a whole one) may reduce 
the accuracy of prediction. For instance, we have 
considered the sample source as well as the tumor 
proportion among samples to be different when our 
samples for groups IE and IIE breast cancers are 
compared to the samples described by Oh et al.1
(5)    More  than  one  gene  products—transcription 
variants  are  differentially  co-regulated  by  two 
transcription  factors  of  interest.  For  example, 
the  bivariate  network  approach  predicts  tumor 
angiogenesis  activities  for  five  patients  shown 
in  Figure  8.  One  patient  (array  ID  5349)  has 
low mRNA levels for both PDGFRB(4503) and 
VEGFA(15367) but showing visible vascularity 
on the sonogram. For this patient, we found an 
elevated mRNA expression of another variant—
VEGFA(1135) but is only predicted to be regu-
lated by promoter use pathways—EE1 and EG 
not EESRRA in group IIE that may explain the 
positive result shown on angiosonogram of array 
5349, in part. However, we still need to confirm 
expression status of PDGFRB for this patient in 
our future experiment.
(6)    CID  has  the  advantage  of  measuring  associa-
tion (designated as subCID) in a small subgroup 
(N ≈ 10). All subCID values were added together 
as the final CID value and it was evaluated as sig-
nificance by its corresponding p value. The sub-
CID values in some subgroups show relatively 
high  as  compared  to  those  in  other  subgroups 
within  a  given  population. This  only  indicates 
more contribution for those subgroups in deter-
mining a particular TF1nTF2-target relationship 
in a given population. To relate CID results with 
the heatmap display and to claim a few subgroups 
to be statistically significant for a given TF1nTF2-
target relationship, we may need increase N num-
ber in those subgroups to confirm results derived 
from studies using small N.
(7)    It is not unusual for uneven data partitioning. After 
hierarchical  clustering,  some  subgroups  in  this 
study have N number ranging from 1 to 33. Statis-
tically, it (N , 10) reaches a critical point for CID 
prediction not to be reliable. Excluding those small 
Ns before CID measurement could be an option. 
However, such strategy has the disadvantage for 
each bivariate CID measurement not based on the 
same population while biologically reproducible 
investigations are made in the same population for Actions of transcription factors on shared target genes
Cancer Informatics 2012:11  131
establishing  the  common  relationship(s)  among 
many transcription factors (N . 2) to control their 
shared target gene expressions.
(8)    To  effectively  increase  the  power  of  network 
approach, we will consider including other clus-
tering methods32 for identifying a variety of com-
binations on transcription factors that selectively 
carry out their functional interactions within the 
same expression profiling data.
conclusions
Together, we have demonstrated a supervised statistical 
approach  using  bivariate  CID  to  predict  the  most 
relevant network of interactions between transcription 
factors in regulating their shared target gene expres-
sions  in  a  population.  Typically,  our  data  mainly 
indicates  bivariate  CID  to  be  successful  in  finding 
the most relevant, alternative pathways for promoter 
use by two given transcription factors in regulating 
their shared target gene expressions in a breast cancer 
population.
First, we have predicted three relevant promoter 
use pathways that were operated by combinatorial 
interactions between ERα and a TF (E2F1 or GATA3 
or ERRα) on the promoter region of their shared tar-
get gene in a breast cancer population, respectively. 
Four unique regulatory mechanisms predicted in each 
promoter use pathway can be statistically identified 
by combined methods of bivariate CID, univariate 
CID  and  Galton-Pearson’s  correlation  coefficient. 
Biologically, those regulatory events involving cross-
talk between two TFs are divided into four distinct 
mechanisms due to the co-regulatory event partially 
dependent on (a) individual transcriptional activities 
from those two TFs (Mechanism 1); (b) a TF dominant 
regulation (Mechanism 2 and Mechanism 3); and (c) 
no individual transcriptional activity from those two 
TFs (Mechanism 4). The expression of a gene may be 
co-regulated by many TFs (N≥2) simultaneously and/
or sequentially. Thus, a simplified model of biologi-
cally pre-programmed gene expression relevant in a 
given population for the ERα involved co-regulatory 
networks  predicted  by  multivariate  CID  was  pro-
posed (Fig. 7). Those predictions have been partially 
validated in vitro.
Second,  this  approach  can  be  very  sensitive  to 
describe the subtle difference between two subtypes 
of breast cancers or between tumor and non-tumor 
tissues. For instance, Figure 8 indicates a promise 
for  the  multivariate  space  of  an  inferred  ERα 
transcriptional regulatory subnetwork, which differ-
entially controls a subset of angiogenesis related gene 
expressions, to be relevant in leading the phenotypic 
difference (i.e. vascularity) between tumor and non-
tumor parts (Figs. 8A and C). We observed the subtle 
difference in combinatorial actions of ESR1, E2F1, 
GATA3 and ESRRA on up regulating genes that pro-
mote tumor vascularity in groups IE and IIE predicted 
by this subnetwork (Fig. 8B). This suggests a possible 
niche for an in silico established multivariate space of 
ERα transcriptional regulatory network in breast can-
cer diagnostic and therapeutic development.
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A few key abbreviations in this study are listed below.
PDGFRB,  platelet-derived growth  factor receptor,   
beta polypeptide; VEGF, vascular endothelial growth 
factor; VEGFA, vascular endothelial growth factor 
A;  ER(-),  negative  status  for  immunochemical 
stain  of  estrogen  receptor;  ER(+),  positive  status 
for  immunochemical  stain  of  estrogen  receptor; 
PR(-),  negative  status  for  immunochemical  stain 
of progesterone receptor; PR(+), positive status for 
immunochemical  stain  of  progesterone  receptor; 
CID,  coefficient  of  intrinsic  dependence;  GPCC, 
Galton  Pearson’s  Correlation  Coefficient;  KEGG, 
Kyoto Encyclopedia of Genes and Genomes; NCBI, 
National  Center  for  Biotechnology  Information; 
CDF,  cumulative  distribution  function;  E2F1,  E2F 
transcription  factor  1;  ESR1,  estrogen  receptor  1; 
ESRRA, estrogen-related receptor alpha; Group IE, 
ER(+)PR(+); Group IIE, ER(+)PR(-).
in vitro: Literally, “in glass”. A term describing 
biological reactions that occur in a laboratory appa-
ratus or test tube.
in vivo: Literally, “in life”. A term describing pro-
cesses that occur within a living cell or organism.
in silico: Literally, “in computer”. A term describ-
ing analyses that are performed in a computer using 
the tools derived from specific algorithms. 
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Figure s1. A heatmap of gene expression pattern for cell cycle signal transduction pathway in groups Ie and IIe as compared to non-tumor part. 
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